Baseline Dual-Energy Computed Tomography Urate Volume Predicts Fulfillment of Gout Remission After Two Years of Urate-Lowering Therapy. [PDF]
Arthritis Care Res (Hoboken)This study aimed to identify variables that predict gout remission in people with erosive gout receiving urate‐lowering therapy.
Tabi-Amponsah AD +10 more
europepmc +2 more sources
Changes in Tophus Composition During
Arthritis care & research, 2023 The gouty tophus is an organized structure composed of monosodium urate (MSU) crystals and chronic inflammatory soft tissue. This dual‐energy computed tomography (DECT) study aimed to determine whether the composition of the tophus changes during urate ...
Leanne Chen +7 more
openalex +2 more sources
Frontiers in Pharmacology, 2022 Dysfunctional missense variant of organic anion transporter 10 (OAT10/SLC22A13), rs117371763 (c.1129C>T; p.R377C), is associated with a lower susceptibility to gout.
Yu Toyoda +15 more
doaj +1 more source
Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study. [PDF]
Rheumatology (Oxford)Objectives Patients with gout need to adhere to medication over time to achieve good outcomes. We assessed self-reported adherence to medication with urate lowering therapy (ULT) 5 years after a treat-to-target intervention and studied how non-adherence ...
Uhlig T +6 more
europepmc +2 more sources
The Effect of Decrease in Serum Urate for the Risk of Gout Flares During Urate-Lowering Therapy Initiation Among Chinese Male Gout Patients: A Prospective Cohort Study. [PDF]
J Inflamm Res, 2023 Purpose Higher baseline serum urate or higher initial urate-lowering medication dose increased risk of gout flares during urate-lowering therapy (ULT) initiation. The decrease in serum urate may play a crucial role in this process.
Pang L +8 more
europepmc +2 more sources
Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. [PDF]
Ann Rheum DisObjective To investigate gout flare rates based on repeated serum urate (SU) measurements in a randomised controlled trial of urate-lowering therapy (ULT), accounting for dropout and death.
Tedeschi SK +4 more
europepmc +2 more sources
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. [PDF]
Arthritis Res TherInformation about gout treatment following pegloticase discontinuation is limited. We found that after discontinuing pegloticase, patients frequently used oral ULTs (86% of those discontinuing pegloticase).
Holladay EE +7 more
europepmc +2 more sources
The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy [PDF]
Rheumatology, 2023 Cindy Cao +7 more
openalex +2 more sources
The many faces of gout: modern treatment concepts
Клинический разбор в общей медицине, 2021 Gout is a systemic disease caused by the deposition of monosodium urate crystals in various tissues and organs with the subsequent development of autoinflammation.
Irina N. Bobkova, Elena S. Kamyshova
doaj +1 more source
Urate-lowering drugs in the treatment of gout: The unknown about the known
Научно-практическая ревматология, 2021 The main direction of drug therapy for gout and other diseases associated with hyperuricemia is the long-term use of drugs aimed at correcting the level of uric acid.
T. S. Panevin +2 more
doaj +1 more source